Investment Thesis

.

Competitive Moat

characterized by its extensive intangible assets, particularly intellectual property (IP) and brand reputation built over decades. The company’s strong portfolio of diabetes medications and oncology treatments provides high switching costs for patients and healthcare providers, as established therapies become entrenched in treatment protocols. This advantage is durable over the next 5-10 years, primarily due to ongoing innovation and patent protections. However, competition from generic drug manufacturers and emerging biotech firms targeting similar therapeutic areas poses a notable threat.

Growth Engine

Future revenue growth for Eli Lilly is expected to stem from both organic avenues and strategic partnerships. The total addressable market (TAM) for diabetes medications alone is growing rapidly, projected to reach $70 billion by 2028, as global diabetes prevalence continues to rise. New product lines, such as innovative GLP-1 receptor agonists, along with potential expansions into emerging markets, will bolster revenue streams. Eli Lilly is actively gaining market share, particularly with its flagship products like Trulicity, which continues to outperform competitors in terms of prescription growth.